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Abstract: Cordycepin, the major active component from Cordyceps militaris, has been reported to significantly inhibit some types of cancer; however, its effects on ovarian cancer are still not well understood. In this study, we
treated human ovarian cancer cells with different doses of cordycepin and found that it dose-dependently reduced
ovarian cancer cell viability, based on Cell counting kit-8 reagent. Immunoblotting showed that cordycepin increased
Dickkopf-related protein 1 (Dkk1) levels and inhibited β-catenin signaling. Atg7 knockdown in ovarian cancer cells
significantly inhibited cordycepin-induced apoptosis, whereas β-catenin overexpression abolished the effects of
cordycepin on cell death and proliferation. Furthermore, we found that Dkk1 overexpression by transfection downregulated the expression of c-Myc and cyclin D1. siRNA-mediated Dkk1 silencing downregulated the expression
of Atg8, beclin, and LC3 and promoted β-catenin translocation from the cytoplasm into the nucleus. These results
suggest that cordycepin inhibits ovarian cancer cell growth, possibly through coordinated autophagy and Dkk1/βcatenin signaling. Taken together, our findings provide new insights into the treatment of ovarian cancer using
cordycepin.
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Introduction
Cordycepin (3’-deoxyadenosine) is the major
bioactive component of Cordyceps militaris
and has been reported to inhibit cell proliferation [1-3], induce apoptosis [4-7], inhibit platelet aggregation, regulate steroidogenesis, and
reduce inflammation [8]. Moreover, cordycepin
possesses anti-tumor activities [9]. However,
studies on cordycepin inducing autophagy-mediated apoptosis through the regulation of Dkk1/β-catenin signaling pathways are not clearly
unknown.
Autophagy is a process of self-degradation of
cellular components [10], and can be consid-

ered as ‘recycling’ process cell undergo in order
to overcome the effects of nutrient deprivation
on the physiological cellular metabolism and to
improve survival [11]; however, it may also
cause cell death [12]. Consequently, autophagy
plays a crucial role in cancer by significantly
inhibiting tumor growth [13, 14]. Microtubuleassociated protein 1A/1B light chain 3 (LC3) is
a soluble protein that is encoded by the MAP1LC3B gene in humans [15]. During autophagy, autophagosomes engulf cytoplasmic components. Concomitantly, a cytosolic form of LC3
(LC3-I) is conjugated to phosphatidylethanolamine to form an LC3-phosphatidylethanolamine
conjugate (LC3-II) [15, 16]. Therefore, the ratio
of LC3-II to LC3-I represents the autophagic
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rate [17, 18]. Beclin and Atg7 are known autophagy-related proteins [19].
Dickkopf-related protein 1 (Dkk1), a negative
regulator of Wnt signaling, is a target of the
β-catenin/TCF pathway and plays an important
role in vertebrate head formation [20, 21]. Wnt
ligands bind to the seven-pass-transmembrane
receptor, Frizzled, and the single-pass low-density lipoprotein coreceptor-related proteins 5
and 6 (LRP5/6) [22]. Dkk1 forms a ternary complex with Dkk1 and LRP5/6, and induces the
rapid endocytosis and removal of LRP5/6 from
the cell surface [23]. Our data reveal a novel
intranuclear link between β-catenin signaling
and its antagonist, Dkk1.
Wnt/β-catenin signaling has been shown to play a crucial role in autophagy [24]. However, the
role of Dkk1 in regulating autophagy remains to
be elucidated. Autophagic and apoptotic programmed cell death, occurring via different
mechanisms, are both implicated in cancer
[25]. The inhibition of the Wnt/β-catenin signaling pathway suppresses survival signals and
induces apoptosis, whereas autophagy is induced through stress-activated signaling pathways [24, 26]. In this study, we found that cordycepin triggers autophagic flux by suppressing the β-catenin signaling pathway. In addition,
cordycepin promoted caspase-3 cleavage by
upregulating Dkk1 expression in ovarian cancer cells. Taken together, our data suggest that
cordycepin inhibits ovarian cancer cell growth,
possibly through coordinated autophagy and
Dkk1/β-catenin signaling.
Materials and methods
Reagents and antibodies
Fetal bovine serum (FBS), Antibiotic-Antimycotic (100X), and phosphate-buffered saline
(PBS) were procured from Gibco™ (Waltham,
MA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) and Cordycepin (3’-deoxyadenosine from C. militaris) were purchased from
Sigma-Aldrich™ (St. Louis, MO, USA). AnnexinV-FLUOS staining kit was purchased from two
different sources, namely Roche Diagnostics
GmbH (Mannheim, Germany) and Sigma-Aldrich™. The transfection reagent, Hilymax, and
Cell counting kit-8 (CCK-8) were purchased
from Dojindo (Dojindo, Japan). Antibodies aga-
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inst PARP1, caspase-8, -9, -3, and β-actin were
purchased from Cell Signaling Technology
(Beverly, MA, USA). Antibodies against Dkk1,
beclin, β-catenin, Atg7, LC3, PCNA, cyclin D1,
Bcl-2, and c-Myc were procured from Santa
Cruz Biotechnology (Dallas, TX, USA).
Cell lines and cytotoxicity
SKOV-3 and OVCAR-3 ovarian cancer cells were
obtained from the American Type Culture
Collection (Rockville, MD, USA), and cultured in
DMEM supplemented with 10% (v/v) FBS and
1% (w/v) penicillin-streptomycin in a humidified
incubator with 5% (v/v) CO2 at 37°C. The cells
were allowed to adhere and grow for 24 h prior
to exposure to cordycepin. In brief, SKOV-3 cells
and OVCAR-3 were seeded in 96-well plates at
a density of 5 × 103 cells/well. After 24 h of
incubation, the cells were treated with various
concentrations of cordycepin for 24 h. The optimal dose (without cytotoxic effects) was determined using the CCK-8 assay (Dojindo). The
absorbance was measured at 450 nm using a
Sunrise microplate absorbance reader (Tecan,
Männedorf, Switzerland), relative to the untreated control in triplicate experiments.
Apoptosis assay
To detect the effect of cordycepin on apoptosis,
we used the Muse Annexin V & Dead Cell reagent (Millipore) following the user’s guide and
the manufacturer’s instructions. SKOV-3 and
OVCAR3 cells were treated with cordycepin for
48 h, harvested by trypsinization and washed
twice in PBS. The harvested cells were centrifuged at 1500 rpm for 5 min and the cell pellet
was suspended in fresh growth media. Next,
100 μL of cells in suspension were transferred
to a new tube, and then added the 100 μL of
the Muse Annexin V and Dead Cell Reagent to
each tubes. For staining, mixed cells were incubated at room temperature for 45 minutes to 1
hour. Measurements were conducted by using
a Muse Cell Analyzer (Millipore, Billerica, MA,
USA). The statistics were shown the percentages of the cells represented by alive, apoptosis
and dead population.
Microarray analysis
Transcriptional profiling of the cordycepin-treated ovarian cancer cells was carried out using a
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human twin 44K cDNA chip. Total RNA was
extracted from vehicle- or cordycepin (100 μg/
mL)-treated SKOV-3 and OVCAR-3 ovarian cancer cells. This was followed by the synthesis of
cDNA probes using 50 mg RNA in the presence
of aminoallyl-dUTP by reverse transcription.
The cDNA was coupled with the Cy3 (vehicle) or
Cy5 dye (cordycepin-treated). Genes were considered to be differentially expressed after a
signiﬁcance analysis of the microarray, when
the global M and log2 (R/G) values exceeded
|1.0| (two-fold) with P < 0.05. The Student’s ttest was applied to assess the statistical signiﬁcance of the differential expression of genes
after cordycepin treatment. To analyze the biological signiﬁcance of the changes, the array
data were categorized into speciﬁc gene groups.
Gene ontology-based network analysis
To study the biological functions of the regulated genes through their interaction network, we
used Ingenuity Pathway Analysis (IPA, http://
www.ingenuity.com) to examine the biological
functions of the differentially regulated genes
and proteins according to ontology-related interaction networks, including apoptosis signaling. Network generation was optimized based
on the obtained expression profiles when possible and was aimed at producing highly connected networks.
Immunoblotting
Total cell lysates were prepared after homogenization in 2 mL of Tris-HCl (20 mM), containing
a protease inhibitor cocktail (Roche), and left
on ice for 30 min before centrifuging (10 min,
12,000 rpm, 4°C). The protein content of the
supernatant was quantified using the BCA
method. Denatured proteins (30 μg) were resolved using 12% SDS-polyacrylamide gel electrophoresis and transferred onto a 0.2-μm
nitrocellulose membrane in a transfer buffer
and kept for 2 h. The membrane was blocked
for 1 h using 5% (w/v) skimmed milk in Trisbuffered saline with Tween-20 (TTBS), followed
by incubation with the indicated appropriately
diluted primary antibodies at room temperature for 2 h or at 4°C overnight. After washing
the membrane three times (5 min each) with
TTBS, it was incubated with horseradish peroxidase-conjugated goat anti-mouse or rabbit
anti-goat IgG (1:2000 dilution) in TTBS contain6892

ing 5% (w/v) skimmed milk at room temperature for 1 h. The membrane was rinsed three
times (5 min each) with 0.1% (v/v) TTBS. An
enhanced chemiluminescence system (Thermo
Scientific) was used to visualize the bands on a
ChemiDoc MP system (Bio-Rad, Hercules, CA,
USA). Densitometric measurement of the bands
was performed using the ImageJ software. Protein levels were quantitatively analyzed after
normalizing with the level of β-actin as the internal control.
Wound healing assay
The Dkk1 plasmid, pCS2-hDkk1-FLAG, was purchased from Addgene (plasmid number, 15494). To specifically silence Dkk1 and Atg7 expression, several siRNAs (Invitrogen) were tested for their capacity to reduce Dkk1 and Atg7
mRNA and protein levels in RNC transfections,
and the most potent siRNAs were used for all
subsequent experiments. A nonspecific siRNA
was used as a negative control siRNA. The plated cells were transfected after 24 h with 100
mol/L siRNA using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen) overnight. The
wound healing assay was conducted on control
siRNA-transfected and siDkk- or overDkk1-transfected cells after seeding them onto a 24well plate (2 × 104 cells/well). After scraping the
cell monolayer with a pipette tip to create a
wound, the cells were treated with cordycepin
(100 μg/mL) for 48 h. The plates were imaged
using the TissueFAXS system (TissueGnostics,
Vienna, Austria). Wound closure was analyzed
by measuring the healed area and the proportion of the migrated cells using the HistoQuest
software (TissueGnostics).
Immunofluorescence microscopy
The cells were fixed with 4% formamide for 15
min at room temperature for 24 h after an
adherent culture was established. Thereafter,
the cell membranes were permeabilized by
treating with PBS containing 0.25% Triton X-100
for 10 min, blocked using TBST containing 1%
BSA (Sigma-Aldrich) for 30 min, and incubated
with the β-catenin primary antibody (Millipore,
USA) for 1 h. The cells were then incubated with
Alexa Fluor 488-conjugated anti-mouse secondary antibody (Cell Signaling Technology) for
1 h in the dark. After treating the cells with 4,
6-diamidino-2-phenylindole, fluorescence images were obtained by using a confocal microscope (Nikon, Japan).
Am J Transl Res 2019;11(11):6890-6906
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Statistical analyses
GraphPad Prism (GraphPad, San Diego, CA,
USA) was used for the statistical analyses.
Intergroup differences were analyzed using the
Student’s t-test. The IC50 values were determined by nonlinear curve fitting using five data
points and expressed as the mean ± SD.
Results
Cordycepin dose-dependently suppresses
ovarian cancer cell growth
Cordycepin dose-dependently inhibits the cell
viability of ovarian cancer cells. We assessed
the effect of cordycepin on the viability of ovarian cancer cells, SKOV-3 and OVCAR-3. We
treated the cells with different concentrations
of cordycepin and found that it inhibits the viability of SKOV-3 cells in a dose-dependent manner (20-100 μg/mL), based on the results of
CCK-8 (Figure 1A). To observe the cell death of
cordycepin-treated SKOV-3 cells, the morphologies of human ovarian cancer cells were compared to those of untreated control cells by
using light microscopy. The morphology of SKOV-3 cells changed drastically after 60 μg/mL
cordycepin treatment for 48 h (Figure 1B). The
ovarian cancer cells began to detach from the
surface of the culture plate and appeared buoyant. Moreover, the cells appeared to be shrunken, resulting in reduced cell volume. These morphological changes preceded apoptosis. On
the other hand, 40 μg/mL cordycepin induced
less drastic changes at 48 h (Figure 1B). Similar
results were obtained for OVCAR-3 cells (Figure
1A and 1B). These data suggest that cordycepin inhibits ovarian cancer cell growth in a
dose-dependent manner.
Cordycepin induces apoptosis in ovarian cancer cells
To evaluate the anti-cancer effect of cordycepin
resulted in apoptosis in human ovarian cancer
cells, we analyzed Annexin V expression on
SKOV-3 and OVCAR3 cells by flow cytometry.
After cordycepin treatment for 48 h, we measured apoptotic cells by Muse Annexin V and
Dead Cell kit. As shown in the representative
plots in Figure 3A, cordycepin potently induced
apoptosis as detected by increased Annexin V
expression in both SKOV-3 and OVCAR3 ovarian cancer cell lines. The addition, total frac-
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tions of apoptosis (early and late apoptosis)
were increased by cordycepin treatment in
dose-dependent manner. The apoptotic fractions of SKOV-3 and OVCAR-3 cells were increased from 3.2% and 2.4% in control group to
18.2% and 8.1% in cordycepin (100 μg/mL)treated group, respectively (Figure 1C).
Cordycepin induces apoptotic gene expression
in ovarian cancer cells
To investigate the genes involved in the cancer
cell growth inhibition effect of cordycepin, microarray analyses of cordycepin (60 μg/mL)treated SKOV-3 and OVCAR-3 ovarian cancer
cells were conducted. Among the 63,785 genes
assayed, 28,858 genes were expressed in the
cordycepin-treated cells. Among 18,553 genes,
cordycepin treatment upregulated and downregulated 784 and 680 genes, respectively, in
comparison to the levels observed in the untreated control, at 48 h. Genes that were increased or decreased by more than 2-fold were categorized as being significant in data mining. Biologically relevant features were constructed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID)
tools (http://david.abcc.ncifcrf.gov/). Lists of
2-fold upregulated and downregulated genes in
cordycepin-treated SKOV-3 ovarian cancer cells
were uploaded to DAVID for gene ontology analysis (Figure 2A). Upregulated genes included
those involved in cell adhesion, inflammatory
response, immune response, cell-cell signaling,
autophagy, chemotaxis, cytokine-mediated signaling pathway, chemokine-mediated signaling
pathway and positive-regulation of tumor necrosis-factor production. Downregulated genes
included those involved in oxidation-reduction
process, cell adhesion, cell surface receptor
signaling pathway, regulation of cell proliferation and gene expression, chloride transmembrane transport, response to toxic substance,
negative regulation of Wnt signaling pathway,
and positive regulation of protein kinase B signaling. The genes upregulated by cordycepin
treatment were compared with potential autophagotic genes by identifying candidate genes using the GeneCards database (http://
www.genecards.org/) (Figure 2B). The intersection obtained by hierarchical clustering is
presented along with the gene lists in Figure
2C. The signaling network of cordycepin-responsive autophagotic genes is shown in Figure
2D.
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Figure 1. Cordycepin dose-dependently inhibits cell viability and induces apoptosis of ovarian cancer cells. A. Cell viability of SKOV-3 and OVCAR-3 cells were measured using the cell counting kit-8 reagent (dojindo) after treatment with indicated concentrations of cordycepin (0, 20, 40, 60, 100 ug/ml) for 24 and 48 h. B. The
cells were exposed to various concentrations of cordycepin (0, 20, 40, 60, 100 ug/ml) for 48 h. C. Flow cytometry analysis was performed in SKOV-3 and OVCAR-3
cell lines after treatment with indicated concentrations of cordycepin (0, 20, 40, 60, 100 ug/ml) for 48 h. Data were normalized to control and represent the mean
± SEM for three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
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Figure 2. Gene expression analysis and signal network of apoptotic genes changed by cordycepin treatment. A. Results of microarray analysis of gene expression
in response to 60 μg/mL of cordycepin for 48 h. Red and green represent more than 2-fold upregulated and downregulated genes, respectively. B. Venn diagram
showing gene expression profiles based on microarray results in SKOV3 cells treated with cordycepin. The overlapped gene were differentially changed (up- and
down-regulated) more than 2-fold, associated with autophagy. C. Lists of autophagy-related genes that were altered more than 2-fold in response to cordycepin. D.
Signal network of the autophagotic genes generated by using a Qiagen IPA. Microarray experiments were performed in triplicate.
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Figure 3. Cordycepin induces apoptosis through upregulation of Dkk1. A. The indicated cell lines were exposed to 0, 20, 60 and 100 μg/mL cordycepin for 12 h, and
whole-cell protein lysates were harvested and analyzed for western blot for cleaved caspase-8, -9, and -3 and cleaved PARP-1. B. SKOV-3 and OVCAR-3 cells were exposed to 0, 20, 60 and 100 μg/mL cordycepin and western blot were performed for Dkk1 in a dose-dependent manner. And the indicated cell lines were exposed to
100 μg/ml cordycepin for 0, 6, and 24 h and western blot were performed for Dkk1. C. siRNA-mediated knockdown of Dkk1 efficiently protected against cordycepininduced apoptosis. Data were normalized to controls and represent the mean ± SEM for three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
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Dkk1 is involved in cordycepin-induced apoptosis
To study the mechanism by which cordycepin
inhibits cell proliferation and induces cell apoptosis, SKOV-3 and OVCAR-3 ovarian cancer cells treated with different doses of cordycepin
(0, 20, 60, and 100 µg/mL) were used for protein expression analysis. Bax pro-apoptotic members were analyzed as target proteins by
immunoblotting. The results showed that the
protein expression levels of cleaved caspase-3,
-8, -9, and -PARP-1 increased significantly after
treatment with cordycepin (Figure 3A). Together, these results imply that cordycepin induced cell apoptosis through caspase dependent pathways. Dkk1 has been shown to be a
key positive regulator of intrinsic apoptosis by
inhibiting the activation of caspases in human
ovarian cancer cells. Therefore, we evaluated
whether cordycepin influences the levels of
Dkk1 in ovarian cancer cells. SKOV-3 and OVCAR-3 cells were treated with different doses of
cordycepin for 6 h interval. We found that cordycepin dose- and time-dependently increased
the levels of Dkk1 (Figure 3B). Moreover, we
silenced Dkk1 using a specific siRNA in SKOV-3
cells to validate its function in cordycepin-induced apoptosis. As shown in Figure 3C, compared with SKOV-3-lacZ cells, SKOV-3-siDkk1
cells significantly protected against cordycepininduced apoptosis. Taken together, Dkk1 expression contributes to cordycepin-induced
apoptosis in human ovarian cancer cells.
Cordycepin increases autophagy-related proteins in ovarian cancer cells by downregulation
of β-catenin levels
We evaluated the molecular mechanisms underlying the inhibitory effects of cordycepin on
ovarian cancer cells and studied the role of
growth-regulatory factors in ovarian cancer. To
investigate whether cordycepin could modulate
autophagy in SKOV-3 cells, the expression of
autophagy-related proteins was determined
after treatment with cordycepin. Following treatment with different doses of cordycepin (0,
20, 60, and 100 µg/mL) for 24 h, SKOV-3 cells
exhibited a significant increase of the ratio of
LC3-II to LC3-I protein and a significant decrease of β-catenin in a dose-dependent manner
compared to the non-treated control cells
(Figure 4A). In addition, autophagy-related proteins, Atg7 and beclin was increased (Figure
4A). To elucidate the potential role of β-cate6899

nin in the regulation of autopahgy signaling, formation of the ratio of LC3-II to LC3-I in SKOV-3
cells was confirmed using immunofluorescence
analysis. As a result, cordycepin also triggered
a punctate immunostaining pattern for LC3,
which is a marker protein of autophagosomes
(Figure 4B). Using transmission electron microscopy (TEM), we visualized the autophagic
morphology of cordycepin-treated SKOV-3 cells
(Figure 4C). The untreated control cells showed
normal organelles without autophagic bodies.
In contrast, cordycepin treatment induced the
formation of phagophores as well as lysosomes
in the cells.
Upregulation of Dkk1 by cordycepin induces
autophagy through abolishing the translocation of β-catenin to nucleus
We evaluated the inhibitory effects of cordycepin on the role of transcription factor for cell
survival of β-catenin. In the previous results,
cordycepin dose- and time-dependently increased Dkk1 (Figure 3B) and downregulated
nuclear β-catenin protein levels (Figure 4A).
Therefore, we confirmed the effects of Dkk1 on
β-catenin by silencing Dkk1 with siRNA and
overexpressing β-catenin. First, the inhibitory
effect of cordycepin on nuclear translocation of
β-catenin was detected through immunoblotting. As a result, in SKOV-3 cells treated with
different doses of cordycepin (0, 20, 60, and
100 µg/mL), cordycepin inhibited β-catenin translocation from the cytoplasm into the nucleus (Figure 5A). Second, to elucidate the potential role of Dkk1 in the regulation of β-catenin
signaling, Dkk1 siRNA was transfected into
SKOV-3 cells. Dkk1 siRNA was transfected into
SKOV-3 cells. As shown in Figure 5B, siRNA
inhibition of Dkk1 upregulated nuclear β-catenin protein levels after cordycepin treatment.
β-catenin nuclear translocation inhibition under
cordycepin was measured by confocal microscopy. These results show that cordycepin effectively attenuates nuclear β-catenin translocation by modulating the Dkk1 signaling pathway.
The overexpression of β-catenin, verified by immunoblotting, diminished the effects of cordycepin on autophagy-associated proteins, Atg7
and beclin, and the LC3-II to LC3-I ratio in SKOV-3 cells (Figure 5C).
Downregulation of Dkk1 decreased the effects
of cordycepin on autophagy
Thus, we verified that β-catenin overexpression
abolishes the effects of cordycepin on autophAm J Transl Res 2019;11(11):6890-6906
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Figure 4. Cordycepin-mediated Dkk1 upregulation increases autophagy by down-regulating β-catenin in ovarian
cancer cells. A. SKOV-3 cells were exposed to 0, 20, and 100 μg/ml cordycepin and western blot were performed
for β-catenin, beclin, Atg7, and LC3. B. Confirmation of autophagosome formation induced by cordycepin by LC3
antibody staining. SKOV-3 cells and OVCAR-3 were cultured for 1 h, stained, and analyzed. C. Morphological ultrastructural appearance of autophagy by transmission electron microscopy (TEM) in cordycepin-treated ovarian cancer cells. Untreated SKOV-3, and SKOV-3 cells were incubated with cordycepin at 40 μg/mL and 100 μg/mL for 48
h. The induction of autophagic cell death by cordycepin was analyzed by TEM. Morphologic findings characteristic
of autophagy are enlarged to highlight the autophagic bodies indicated by the arrows. White arrows indicate phagophores/autophagosomes and red arrows indicate lysosomes/autolysosomes. Representative images are shown.
Data represent the mean ± SEM for three independent experiments each *P < 0.05, **P < 0.01, ***P < 0.001.

agy. Furthermore, we evaluated the effects of
cordycepin on Dkk1 in SKOV-3 cells after silencing Dkk1 with siRNA, which was verified by
immunoblotting (Figure 5D). Consequently, the
effects of cordycepin on autophagy-associated
proteins, Atg7 and beclin, and the LC3-II to
LC3-I ratio were reduced in SKOV-3 cells. Thus,
we verified that Dkk1 silencing abolishes the
effects of cordycepin on autophagy. Furthermore, cordycepin (100 µg/mL) induced Dkk1
overexpression, which was confirmed at the
transcriptional level (Figure 5E), while si-Dkk1
increased the migration of SKOV-3 cells in the
wound healing assay (Figure 5F).
Cordycepin causes autophagy-triggered apoptosis in ovarian cancer cells
Since cordycepin induces apoptosis as well as
autophagy in human ovarian cancer cells, we
further explored the relationship between cordycepin-induced apoptosis and autophagy. An
siRNA was used to inhibit Atg7 expression in
ovarian cancer cells, and then apoptosis-related proteins were quantified by western blot
analysis. These findings demonstrated that Atg7 silencing significantly abrogated cordycepininduced cleavage of caspase-3 and PARP1 (Figure 6A). Moreover, autophagy inhibitors, such
as LY294002 and chloroquine (CQ), which block the upstream and downstream steps of
autophagy, respectively, were used to examine
the impact of autophagy on apoptosis. We inhibited autophagy in SKOV-3 cells using LY294002 and CQ and analyzed the effects on
the level of LC3-II and cordycepin-induced cell
death. LY294002 is an inhibitor of PI3K, which
inhibits autophagosome accumulation and inhibits the conversion of LC3-I to LC3-II. However,
CQ, a lysosome inhibitor, could induce the aggregation of autophagosomes and increase
LC3-II levels by blocking the fusion of autophagosomes and lysosomes. Western blot analysis
indicated that cordycepin-induced autophagy
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was successfully inhibited by LY294002 and
CQ (Figure 6B). To further understand the biological role of autophagy in cordycepin-induced
cell death, we examined the changes of cordycepin-induced apoptosis. The results demonstrated that cordycepin in combination with
LY294002 and CQ treatment reduced the cleavage of caspase 3 (Figure 6B), compared
with cordycepin treatment alone, whereas cells
treated with LY294002 and CQ showed antiapoptosis-inducing effects on SKOV-3 cells.
These results suggest that the inhibition of
autophagy attenuates cordycepin-induced apoptosis, indicating that autophagy plays a crucial role in cordycepin-induced cell death in
SKOV-3 cells.
Discussion
Although cordycepin-induced cell death has
been reported, the molecular mechanisms
underlying the relationship between cordycepin-induced apoptosis and autophagy have not
been elucidated in ovarian cancer. Here, we
focused on understanding the fundamental
mechanisms of cordycepin-induced apoptosis
and examined the relationship between apoptosis and autophagy. Cordycepin induces apoptosis in human ovarian cancer cells through
extrinsic and intrinsic signaling pathways primarily regulated by Bcl-2 pro-apoptotic proteins
[27]. Additionally, cordycepin induces the mitochondrial translocation of Bax in a dose-dependent manner, causing the release of cytochrome c and the activation of caspases [28]. In
the present study, we found that cordycepin
reduces the viability of human ovarian cancer
cells in a dose- and time-dependent manner,
verifying its apoptotic potential. In addition,
flow cytometry analysis revealed that approximately 40% of SKOV-3 and OVCAR-3 cells
exhibit early- and late-phase apoptosis after
exposure to cordycepin (100 μg/mL) for 48 h
(Figure 1C). Moreover, the cleaved forms of
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Figure 5. Overexpression of β-catenin and downregulation of Dkk1 abolishes the effects of cordycepin on autophagy. A. The indicated cell lines were exposed to 0,
20, and 100 μg/mL cordycepin and western blot analysis was performed for measuring translocation of β-catenin from cytosol to nucleus. B. β-catenin localization
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was examined by immunofluorescence analysis after 24 h of Dkk1 siRNA transfection or cordycepin treatment. C. SKOV-3 cells were overexpressed with β-catenin
or treated with cordycepin. And then, western blotting was performed for β-catenin, beclin, Atg7, and LC3. D. Western blotting for Dkk1, beclin, Atg7, and LC3 in
Dkk1-silenced or cordycepin treated SKOV-3 cells. E. To assess the effect of Dkk1 downregulation on β-catenin expression, western blotting was performed for Dkk1,
β-catenin, PCNA, cyclin D1 and c-Myc. F. The effect of si-Dkk1 on the migration of SKOV-3 cells was analyzed using the wound healing assay. Data represent the
mean ± SEM for three independent experiments each *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 6. Cordycepin induces pro-apoptotic autophagy in SKOV-3 cells. A. SKOV-3 cells conducted with Atg7 siRNA transfection and exposed to 0, 60, and 100 μg/
mL cordycepin for 12 h was analyzed by western blot for Atg7, caspase-3, and PARP. B. Cordycepin promotes apoptosis through activating autophagy in SKOV-3 cells.
SKOV-3 cells were pretreated with 10 μM LY294002 or 20 μM CQ for 1 h, and then exposed to 100 μg/mL cordycepin for another 12 h. Data represent the mean ±
SEM for three independent experiments each *P < 0.05, **P< 0.01, ***P < 0.001.
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caspase-9, caspase-3, and PARP1 increased in
a dose- and time-dependent manner (Figure
3A), suggesting that cordycepin induces extrinsic as well as intrinsic apoptosis in human ovarian cancer cells. Dkk1 has been previously
shown to positively regulate apoptosis by inhibiting the activation of caspases in human cancer cells [29]. Thus, we assessed the mechanism of cordycepin-induced apoptosis, and
found that cordycepin increases Dkk1 expression (Figure 3B). However, Dkk1 silencing protected SKOV-3 cells from cordycepin-induced
apoptosis (Figure 3C). These results suggest
that the expression of Dkk1 contributes to
cordycepin-induced apoptosis in human ovarian cancer cells. Dkk1, a negative regulator of
Wnt signaling, is a target of the β-catenin/TCF
pathway [30]. Nuclear β-catenin activates cMyc, cyclin D1, and c-jun to promote cell proliferation, and activates Bcl-2 to inhibit apoptosis
[31]. In this study, we found that cordycepin
dose- and time-dependently increases the levels of Dkk1 (Figure 3B), autophagy-related proteins, Atg7, and beclin (Figure 4A). It also increased the LC3-II to LC3-I ratio in SKOV-3 cells
in a dose-dependent manner (Figure 4A) and
decreased β-catenin levels as compared to the
non-treated control cells in a dose-dependent
manner. We found that cordycepin also triggered a punctate immunostaining pattern for
LC3, which is a marker protein of autophagosomes (Figure 4B). Moreover, siRNA inhibition
of Dkk1 upregulated nuclear β-catenin protein
levels after cordycepin treatment. The inhibition of the nuclear translocation β-catenin by
cordycepin was detected by immunoblotting
and confocal microscopy (Figure 5A, 5B). These
results show that cordycepin effectively attenuates nuclear β-catenin translocation by upregulating the Dkk1 signaling pathway.
Autophagy is induced in β-catenin-deficient
cancer cells via Bax activation [24]. In addition,
through the immunofluorescence analysis, βcatenin overexpression diminished the dosedependent effects of cordycepin on the autophagy-associated proteins, Atg7 and beclin, and
the LC3-II to LC3-I ratio (Figure 5C). However,
β-catenin expression was significantly attenuated by Dkk1, and the autophagic effects of
cordycepin were abolished by Dkk1 knockdown
(Figure 5D, 5E). These findings suggest that
cordycepin induces autophagy through the downregulation of β-catenin and the upregulation
of Dkk1 expression. The relationship between
6904

autophagy and apoptosis or other forms of cell
death is complicated and poorly understood
[32]. Under stress, cells exhibit autophagy as
an adaptive mechanism to avoid stress-induced
apoptosis [33]. Cordycepin induces autophagymediated c-FLIPL degradation, which leads to
apoptosis in human non-small cell lung cancer
cells [34]. However, the molecular mechanisms
of autophagy-triggered apoptosis are not well
understood. β-catenin silencing induces autophagy and apoptosis in MM cells [24]. We found
that inhibiting autophagy by silencing Atg7
expression significantly abrogated cordycepininduced cleavage of caspase-3 and PARP1
(Figure 6A), indicating that cordycepin induces
autophagy-triggered apoptosis in ovarian cancer cells. To clarify this, we inhibited cordycepin-induced autophagy pharmacologically by
using LY294002 and CQ in SKOV-3 cells (Figure
6B). We found that cordycepin-induced cell
death significantly decreased by additional
treatment with LY294002 and CQ, indicating
that cordycepin-induced autophagy might play
a cytotoxic role in SKOV-3 cells. To further confirm the cytoprotective role of autophagy induced by cordycepin in SKOV-3 cells, we detected apoptosis in SKOV-3 cells when cells were
treated with cordycepin and autophagy inhibitors. Remarkably, treatment with LY294002
and CQ attenuated cordycepin-induced apoptosis, as evidenced by decreased caspase-3 cleavage. These results demonstrate that cordycepin-induced autophagy plays a cytotoxic role
in SKOV-3 cells. Blocking autophagy could attenuate the efficacy of cordycepin in SKOV-3
cells and could be a promising new therapeutic
strategy for ovarian cancer.
In summary, our results demonstrate that cordycepin triggers Dkk1-mediated autophagy by
suppressing the β-catenin signaling pathway. In
addition, cordycepin promotes the cleavage of
caspase-3 by inducing autophagy in ovarian
cancer cells. Our findings describe the molecular mechanisms of apoptosis induced by cordycepin, which may provide a theoretical basis for
the application of cordycepin derivatives in cancer treatment.
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